Press Releases
-
Aug 4, 2020- Fireside chat will address KRAS inhibition and the promise of onvansertib as a new therapeutic option in colorectal cancer
-
Jun 15, 2020- Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels